FDA-approves the First Therapy in 2018 for the Seizures Associated With Dravet Syndrome

NeuroPharmac Journal
doi 10.37881/1.412
Full Text
Abstract

Available in full text

Date
Authors
Publisher

NeuroPharmac Journal

Related search

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine
Medicine
2017English

FDA Approves First Biosimilar to Treat Cancer

Cancer Discovery
Oncology
2017English

FDA Approves Test for TB

Infection Control and Hospital Epidemiology
EpidemiologyInfectious DiseasesMicrobiology
1997English

Perineal Stimulation Triggering Seizures in a Child With Dravet Syndrome

Seizure : the journal of the British Epilepsy Association
MedicineNeurology
2018English

FDA Approves Kadcyla for Breast Cancer

Cancer Discovery
Oncology
2013English

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

JAMA Neurology
Neurology
2020English

Cannabidiol: FDA Approved New Drug for the Lennox-Gastaut Syndrome and Dravet Syndrome: Pharmacotherapeutics Review

NeuroPharmac Journal
2019English

FDA Approves Breakthrough Immunotherapy for Patients With Non-Small-Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Pharmacotherapy of Seizures Associated With Lennox-Gastaut Syndrome

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy